313 Long-Term Outcome After Infliximab Withdrawal for Sustained Remission in Crohn's Disease
Cathérine Reenaers(Centre Hospitalier Universitaire de Liège), Édouard Louis(Centre Hospitalier Universitaire de Liège), Philippe Marteau(Eaton (Taiwan)), Arnaud Boureille, Aurélien Amiot(Université Paris-Est Créteil), Matthieu Allez(Inserm), Benoît Coffin(Inserm), Bernard Flourié(Hôpital Saint Lazare), Guillaume Savoye(Université de Rouen Normandie), Yoram Bouhnik(Clinique Ambroise Paré), Lucine Vuitton(Centre Hospitalier Universitaire de Besançon), Georgia Malamut(Délégation Paris 5), Romain Altwegg(Université de Montpellier), Maria Nachury(Centre Hospitalier Universitaire de Lille), Martine De Vos(Ghent University Hospital), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Jean‐Louis Dupas(Centre Hospitalier Universitaire Amiens-Picardie), Stéphanie Viennot(Centre Hospitalier Universitaire de Besançon), Jean–Yves Mary(Inserm), David Laharie(Université de Bordeaux)
Cited by 7
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Potential of fecal microbiota for early‐stage detection of colorectal cancer
|Molecular Systems Biology|2014|1.4k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k